IP Library › Granted Patent US 7,371,767

Granted Patent B2

US 7,371,767 · App. 10/499,393 · Granted May 13, 2008

Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,371,767
App. No.: 10/499,393
Granted: May 13, 2008
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Pyrrole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, circadian rhythm disorders, and other diseases.

Claims (65)

1. A compound of the Formula (I):

wherein:

X and Y each independently is aryl or heteroaryl wherein at least one of X and Y is a heteroaryl with N adjacent to the position of attachment to A or B respectively;

X is optionally substituted with 1-7 independent halogen, —CN, NO 2 , —C 1-6 alkyl, —C 1-6 alkenyl, —C 1-6 alkynyl, —OR 1 , —NR 1 R 2 , —C(═NR 1 )NR 2 R 3 , —N(═NR 1 )NR 2 R 3 , —NR 1 COR 2 , —NR 1 CO 2 R 2 , —NR 1 SO 2 R 4 , —NR 1 CONR 2 R 3 , —SR 4 , —SOR 4 , —SO 2 R 4 , —SO 2 NR 1 R 2 , —COR 1 , —CO 2 R 1 , —CONR 1 R 2 , —C(═NR 1 )R 2 , or —C(═NOR 1 )R 2 substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the —C 1-6 alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —O(heteroaryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), or —N(C 0-6 alkyl)(aryl) groups;

R 1 , R 2 , and R 3 each independently is —C 0-6 alkyl, —C 3-7 cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, ——O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —O(heteroaryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), —N(C 0-6 alkyl)(aryl) substituents;

R 4 is C 1-6 alkyl, —C 3-7 cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —O(heteroaryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), —N(C 0-6 alkyl)(aryl) substituents;

A is —C 0-4 alkyl, —C 0-2 alkyl-SO—C 0-2 alkyl-, —C 0-2 alkyl-SO 2 —C 0-2 alkyl-, —C 0-2 alkyl-CO—C 0-2 alkyl-, —C 0-2 alkyl-NR 9 CO—C 0-2 alkyl-, —C 0-2 alkyl-NR 9 SO 2 -C 0-2 alkyl or heteroC 0-4 alkyl;

Y is optionally substituted with 1-7 independent halogen, —CN, NO 2 , —C 1-6 alkyl, —C 1-6 alkenyl, —C 1-6 alkynyl, —OR 5 , —NR 5 R 6 , —C(═NR 5 )NR 6 R 7 , —N(═NR 5 )NR 6 R 7 , —NR 5 COR 6 , —NR 5 CO 2 R 6 , —NR 5 SO 2 R 8 , —NR 5 CONR 6 R 7 , —SR 8 , —SOR 8 , —SO 2 R 8 , —SO 2 NR 5 R 6 , —COR 5 , —CO 2 R 5 , —CONR 5 R 6 , —C(═NR 5 )R 6 , or —C(═NOR 5 )R 6 substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the C 1-6 alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —O(heteroaryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), or —N(C 0-6 alkyl)(aryl) groups;

R 5 , R 6 , and R 7 each independently is —C 0-6 alkyl, —C 3-7 cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —O(heteroaryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), —N(C 0-6 alkyl)(aryl) substituents;

R 8 is —C 1-6 alkyl, —C 3-7 cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —O(heteroaryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), —N(C 0-6 alkyl)(aryl) substituents;

B is —C 0-4 alkyl, —C 0-2 alkyl-SO—C 0-2 alkyl-, —C 0-2 alkyl-SO 2 —C 0-2 alkyl-, —CO 2 alkyl-CO—C 0-2 alkyl-, C 0-2 alkyl-NR 10 CO—C 0-2 alkyl-, —C 0-2 alkyl-NR 10 SO 2 C 0-2 alkyl or heteroC 0-4 alkyl;

R 9 and R 10 each independently is —C 0-6 alkyl, —C 3-7 cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —O(heteroaryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), —N(C 0-6 alkyl)(aryl) substituents;

R 11 , R 12 and R 13 is each independently halogen, —C 0-6 alkyl, —C 0-6 alkoxyl, ═O, ═N(C 0-4 alkyl),or —N(C 0-4 alkyl)(C 0-4 alkyl), wherein optionally two of R 11 , R 12 and R 13 are combined to form a cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring fused to the pyrrole moiety; wherein the —C 1-6 alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —O(heteroaryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), or —N(C 0-6 alkyl)(aryl) groups;

any N may be an N-oxide; and

wherein any of the alkyl optionally is substituted with 1-9 independent halogens;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein:

X is 2-pyridyl optionally substituted with 1-4 independent halogen, —CN, NO 2 , —C 1-6 alkyl, —C 1-6 alkenyl, —C 1-6 alkynyl, —OR 1 , —NR 1 R 2 , —C(═NR 1 )NR 2 R 3 , —N(═NR 1 )NR 2 R 3 , —NR 1 COR 2 , —NR 1 CO 2 R 2 , —NR 1 SO 2 R 4 , —NR 1 CONR 2 R 3 , —SR 4 , —SOR 4 , —SO 2 R 4 , —SO 2 NR 1 R 2 , —COR 1 , —CO 2 R 1 , —CONR 1 R 2 , —C(═NR 1 )R 2 , or —C(═NOR 1 )R 2 substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the —C 1-6 alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —O(heteroaryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), or —N(C 0-6 alkyl)(aryl) groups.

3. The compound of claim 2 wherein:

Y is phenyl optionally substituted with 1-5 independent halogen, —CN, NO 2 , —C 1-6 alkyl, —C 1-6 alkenyl, —C 1-6 alkynyl, —OR 1 , —NR 1 R 2 , —C(═NR 1 )NR 2 R 3 , —N(═NR 1 )NR 2 R 3 , —NR 1 COR 2 , —NR 1 CO 2 R 2 , —NR 1 SO 2 R 4 , —NR 1 CONR 2 R 3 , —SR 4 , —SOR 4 , —SO 2 R 4 , —SO 2 NR 1 R 2 , —COR 1 , —CO 2 R 1 , —CONR 1 R 2 , —C(═NR 1 )R 2 , or —C(═NOR 1 )R 2 substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the —C 1-6 alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl),

—O(heteroaryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), or —N(C 0-6 alkyl)(aryl) groups.

4. The compound of claim 1 wherein:

Y is 2-pyridyl optionally substituted with 1-4 independent halogen, —CN, NO 2 , —C 1-6 alkyl, —C 1-6 alkenyl, —C 1-6 alkynyl, —OR 1 , —NR 1 R 2 , —C(═NR 1 )NR 2 R 3 , —N(═NR 1 )NR 2 R 3 , —NR 1 COR 2 , —NR 1 CO 2 R 2 , —NR 1 SO 2 R 4 , —NR 1 CONR 2 R 3 , —SR 4 , —SOR 4 , —SO 2 R 4 , —SO 2 NR 1 R 2 , —COR 1 , —CO 2 R 1 , —CONR 1 R 2 , —C(═NR 1 )R 2 , or —C(═NOR 1 )R 2 substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the —C 1-6 alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —O(heteroaryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), or —N(C 0-6 alkyl)(aryl) groups.

5. The compound of claim 4 wherein:

X is pyridyl optionally substituted with 1-4 independent halogen, —CN, NO 2 , —C 1-6 alkyl, —C 1-6 alkenyl, —C 1-6 alkynyl, 1 , NR 1 R 2 , —C(═NR 1 )NR 2 R 3 , —N(═NR 1 )NR 2 R 3 , —NR 1 COR 2 , —NR 1 CO 2 R 2 , —NR 1 SO 2 R 4 , —NR 1 CONR 2 R 3 , —SR 4 , —SOR 4 , —SO 2 R 4 , —SO 2 NR 1 R 2 , —COR 1 , —CO 2 R 1 , —CONR 1 R 2 , —C(NR 1 )R 2 , or —C(═NOR 1 )R 2 substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the —C 1-6 alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —O(heteroaryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), or —N(C 0-6 alkyl)(aryl) groups.

6. The compound of claim 1 wherein:

X is phenyl optionally substituted with 1-5 independent halogen, —CN, NO 2 , —C 1-6 alkyl, —C 1-6 alkenyl, —C 1-6 alkynyl, —OR 1 , —NR 1 R 2 , —C(═NR 1 )NR 2 R 3 , —N(═NR 1 )NR 2 R 3 , —NR 1 COR 2 , —NR 1 CO 2 R 2 , —NR 1 SO 2 R 4 , —NR 1 CONR 2 R 3 , —SR 4 , —SOR 4 , —SO 2 R 4 , —SO 2 NR 1 R 2 , —COR 1 , —CO 2 R 1 , —CONR 1 R 2 , —C(═NR 1 )R 2 , or —C(═NOR 1 )R 2 substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the —C 1-6 alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —O(heteroaryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), or —N(C 0-6 alkyl)(aryl) groups.

7. The compound of claim 6 wherein:

Y is 2-pyridyl optionally substituted with 1-4 independent halogen, —CN, NO 2 , —C 1-6 alkyl, —C 1-6 alkenyl, —C 1-6 alkynyl, —OR 1 , —NR 1 R 2 , —C(═NR 1 )NR 2 R 3 , —N(═NR 1 )NR 2 R 3 , —NR 1 COR 2 , —NR 1 CO 2 R 2 , —NR 1 SO 2 R 4 , —NR 1 CONR 2 R 3 , —SR 4 , —SOR 4 , —SO 2 R 4 , —SO 2 NR 1 R 2 , —COR 1 , —CO 2 R 1 , —CONR 1 R 2 , —C(═NR 1 )R 2 , or —C(═NOR 1 )R 2 substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the —C 1-6 alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, —Cn, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —O(heteroaryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), or —N(C 0-6 alkyl)(aryl) groups.

8. The compound of claim 1 wherein:

Y is 1,3-thiazol-2-yl optionally substituted with 1-2 independent halogen, —CN, NO 2 , —C 1-6 alkyl, —C 1-6 alkenyl, —C 1-6 alkynyl, —OR 1 , —NR 1 R 2 , —C(═NR 1 )NR 2 R 3 , —N(═NR 1 )NR 2 R 3 , —NR 1 COR 2 , —NR 1 CO 2 R 2 , —NR 1 SO 2 R 4 , —NR 1 CONR 2 R 3 , —SR 4 , —SOR 4 , —SO 2 R 4 , —SO 2 NR 1 R 2 , —COR 1 , —CO 2 R 1 , —CONR 1 R 2 , —C(═NR 1 )R 2 , or —C(═NOR 1 )R 2 substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the —C 1-6 alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, —Cn, C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —O(heteroaryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), or —N(C 0-6 alkyl)(aryl) groups.

9. The compound of claim 8 wherein:

X is phenyl optionally substituted with 1-5 independent halogen, —Cn, NO 2 , —C 1-6 alkyl, —C 1-6 alkenyl, —C 1-6 alkynyl, —OR 1 , —NR 1 R 2 , —C(═NR 1 )NR 2 R 3 , —N(═NR 1 )NR 2 R 3 , —NR 1 COR 2 , —NR 1 CO 2 R 2 , —NR 1 SO 2 R 4 , —NR 1 CONR 2 R 3 , —SR 4 , —SOR 4 , —SO 2 R 4 , —SO 2 NR 1 R 2 , —COR 1 , —CO 2 R 1 , —CONR 1 R 2 , —C(═NR 1 )R 2 , or —C(═NOR 1 )R 2 substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the —C 1-6 alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —O(heteroaryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), or —N(C 0-6 alkyl)(aryl) groups.

10. The compound of claim 1 wherein:

Y is pyrazolyl optionally substituted with 1-3 independent halogen, —Cn, NO 2 , —C 1-6 alkyl, —C 1-6 alkenyl, —C 1-6 alkynyl, —OR 1 , —NR 1 R 2 , —C(═NR 1 )NR 2 R 3 , —N(═NR 1 )NR 2 R 3 , —NR 1 COR 2 , —NR 1 CO 2 R 2 , —NR 1 SO 2 R 4 , —NR 1 CONR 2 R 3 , —SR 4 , —SOR 4 , —SO 2 R 4 , —SO 2 NR 1 R 2 , —COR 1 , —CO 2 R 1 , —CONR 1 R 2 , —C(═NR 1 )R 2 , or —C(═NOR 1 )R 2 substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the —C 1-6 alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, —Cn, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —O(heteroaryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), or —N(C 0-6 alkyl)(aryl) groups.

11. The compound of claim 10 wherein:

X is phenyl optionally substituted with 1-5 independent halogen, —Cn, NO 2 , —C 1-6 alkyl, —C 1-6 alkenyl, —C 1-6 alkynyl, —OR 1 , —NR 1 R 2 , —C(═NR 1 )NR 2 R 3 , —N(═NR 1 )NR 2 R 3 , —NR 1 COR 2 , —NR 1 CO 2 R 2 , —NR 1 SO 2 R 4 , —NR 1 CONR 2 R 3 , —SR 4 , —SOR 4 , —SO 2 R 4 , —SO 2 NR 1 R 2 , —COR 1 , —CO 2 R 1 , —CONR 1 R 2 , —C(═NR 1 )R 2 , or —C(═NOR 1 )R 2 substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the —C 1-6 alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, —Cn, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —O(heteroaryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), or —N(C 0-6 alkyl)(aryl) groups.

12. A compound which is selected from the group consisting of:

3-(1-pyridin-2-yl-1H-pyrrol-3-yl)benzonitrile;

2-[3-(3-chiorophenyl)-1H-pyrrol-1-yl]pyridine;

2-[3-(3-methoxyphenyl)-1H-pyrrol-1-yl]pyridine;

3-(3-pyridin-2-yl-1H-pyrrol-1-yl)benzonitrile;

2-{1-[3-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl}pyridine;

2-[1-(3,5-dichiorophenyl)-1H-pyrrol-3-yl]pyridine;

2-[1-(3-methylphenyl)-1H-pyrrol-3-yl]pyridine;

2-[1-(3-methoxyphenyl)-1H-pyrrol-3-yl]pyridine;

3-[3-(1,3-thiazol-2-yl)-1H-pyrrol-1-yl]benzonitrile;

3-fluoro-5-(3-pyridin-2-yl-1H-pyrrol-1-yl)benzonitrile;

3-(3-bromo-4-pyridin-2-yl-1H-pyrrol-1-yl)-5-fluorobenzonitrile;

3-fluoro-5-(3-methyl-4-pyridin-2-yl-1H-pyrrol-1-yl)benzonitrile;

3-(3-chloro-4-pyridin-2-yl-1H-pyrrol-1-yl)-5-fluorobenzonitrile;

3-fluoro-5-[3-(1H-pyrazol-1-yl)-1H-pyrrol-1-yl]benzonitrile;

2-chloro-6-(3-pyridin-2-yl-1H-pyrrol-1-yl)pyridine;

2-(pyridin-3-yloxy)-6-(3-pyridin-2-yl-1H-pyrrol-1-yl)pyridine;

2-chloro-4-methyl-6-(3-pyridin-2-yl-1H-pyrrol-1-yl)pyridine;

3-chloro-5-(3-pyridin-2-yl-1H-pyrrol-1-yl)benzonitrile;

2-{1-[3-fluoro-5-(pyridin-3-yloxy)phenyl]-1H-pyrrol-3-yl}pyridine;

3-bromo-5-(3-pyridin-2-yl-1H-pyrrol-1-yl)benzonitrile;

3-methyl-5-(3-pyridin-2-yl-1H-pyrrol-1-yl)benzonitrile;

3-fluoro-5-[3-(1,3-thiazol-2-yl)-1H-pyrrol-1-yl]benzonitrile;

or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

14. A pharmaceutical composition comprising the compound of claim 12 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

15. A method of treatment or prevention of pain comprising the step of administering a therapeutically effective amount or a prophylactically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.

16. A method of treatment or prevention of a pain disorder wherein the pain disorder is acute pain, persistent pain, chronic pain, inflammatory pain or neuropathic pain, comprising administering a therapeutically effective amount or a prophylactically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.

Assignments (1)

CHANGE OF NAME Recorded Jan 29, 2010

From: MERCK & CO., INC.

To: MERCK SHARP & DOHME CORP.

Reel/Frame 023861/0910 →